title: Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome.
abstract: Limited information is available on the identity of antigens targeted by antibodies present in cerebrospinal fluid (CSF) of patients with clinically isolated syndrome (CIS). The aim of this study was to identify novel antigens for CIS and investigate their prognostic potential to predict conversion to multiple sclerosis (MS). We applied serological antigen selection (SAS) to identify antigens interacting with antibodies present in the pooled CSF from four CIS patients, who developed MS. Antibody reactivity towards CIS antigens identified by SAS was tested in CSF and serum from patients with CIS (n = 123/n = 108), MS (n = 65/n = 44), and other (inflammatory) neurological diseases (n = 75/n = 38) as well as in healthy control sera (n = 44). Using SAS, a panel of six novel CIS candidate antigens was identified. CSF antibody reactivity was detected in both CIS and relapsing-remitting (RR) MS. Serum reactivity was significantly increased in CIS and RR-MS as compared with controls (p = 0.03). For two antigens, the frequency of antibody-positive patients was higher in CIS patients who converted to MS as compared with CIS patients without conversion. We identified novel CIS antigens to which antibody reactivity was primarily detected in CIS and RR-MS as compared to controls. Possible prognostic potential could be demonstrated for two antigens.
authors.affiliation: Hasselt University, Biomedical Research Institute (BIOMED) and transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium.
authors.forename: Myrthe
authors.initials: M
authors.lastname: Rouwette
authors.forename: Klaartje
authors.initials: K
authors.lastname: Somers
authors.forename: Cindy
authors.initials: C
authors.lastname: Govarts
authors.forename: Peter P
authors.initials: PP
authors.lastname: De Deyn
authors.forename: Raymond
authors.initials: R
authors.lastname: Hupperts
authors.forename: Bart
authors.initials: B
authors.lastname: Van Wijmeersch
authors.forename: Brigit A
authors.initials: BA
authors.lastname: De Jong
authors.forename: Marcel M
authors.initials: MM
authors.lastname: Verbeek
authors.forename: Vincent
authors.initials: V
authors.lastname: Van Pesch
authors.forename: Christian
authors.initials: C
authors.lastname: Sindic
authors.forename: Luisa M
authors.initials: LM
authors.lastname: Villar
authors.forename: José C
authors.initials: JC
authors.lastname: Álvarez-Cermeño
authors.forename: Piet
authors.initials: P
authors.lastname: Stinissen
authors.forename: Veerle
authors.initials: V
authors.lastname: Somers
mesh_terms: D000293:Adolescent; D000328:Adult; D000937:Antigen-Antibody Reactions; D000941:Antigens / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood* / Q000134:cerebrospinal fluid*; D003711:Demyelinating Diseases / Q000097:blood* / Q000134:cerebrospinal fluid*; D004185:Disability Evaluation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D051863:Host Cell Factor C1 / Q000276:immunology; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000097:blood / Q000134:cerebrospinal fluid; D009185:Myelin Proteins / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology / Q000302:isolation & purification; D011237:Predictive Value of Tests; D012698:Serologic Tests
chemical_list: D000941:Antigens; D001323:Autoantibodies; C497692:HCFC1 protein, human; D051863:Host Cell Factor C1; D009185:Myelin Proteins; D010446:Peptide Fragments